神经退行和NMDA的产生
K Gulyaeva1, M Fokin1, D Kachanov1
1North-Western Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia; S.M. Kirov Military Medical Academy, Saint-Petersburg, Russia; Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia.
Georgian medical news
|July 31, 2023
概括
N-甲基D-酸盐 (NMDA) 受体对于记忆等大脑功能至关重要. 它随着年龄的增长和某些药物的使用而下降,会影响大脑健康,强调需要了解它在神经退行性疾病中的作用.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- N-甲基D-酸盐 (NMDA) 受体是人类大脑功能中的关键参与者,特别是在海马和皮质等区域.
- 它的有效功能对关联记忆,学习和维持突触密度至关重要.
研究的目的:
- 探索NMDA受体在大脑中的分布和功能意义.
- 研究衰老和药物干预对NMDA受体数量和结构的影响.
- 了解NMDA受体对抗剂在神经疾病中的治疗潜力和局限性.
主要方法:
- 放射性配体分析被用来确定NMDA受体的密度和分布.
- 对研究的文献综述,研究了与年龄相关的变化以及抗抑郁药和对抗剂对NMDA受体的影响.
主要成果:
- 在海马体,条体,皮质和杏仁体中观察到NMDA受体密度最高.
- 衰老和选择性血清素再吸收抑制剂 (SSRI) 的使用与NMDA受体数量的减少和形态的改变有关.
- 像孟坦丁这样的NMDA受体对手在控制阿尔茨海默病症状方面表现出潜力,而胺的使用受到副作用的限制.
结论:
- 了解NMDA受体的组成,信号和与年龄相关的变化对于预防神经退行性疾病至关重要.
- NMDA受体功能与认知过程直接相关,易受各种生理和药理影响.
相关概念视频
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Alzheimer's Disease: Overview
522
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
522
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
155
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
155
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
Long-term Potentiation
2.8K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
Hebbian LTP
LTP can occur when...
2.8K
Alzheimer's Disease: Treatment
218
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
218


